Sionna Financial Statements From 2010 to 2026

SION Stock   39.11  0.26  0.67%   
Sionna Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Sionna Therapeutics' valuation are provided below:
Market Capitalization
1.7 B
Earnings Share
(1.80)
We have found ninety-seven available fundamental trend indicators for Sionna Therapeutics Common, which can be analyzed and compared to other ratios and to its competition. Self-guided Investors are advised to double-check Sionna Therapeutics' current fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road.
Check Sionna Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sionna Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 9.9 M, Interest Income of 9.9 M or Depreciation And Amortization of 503.4 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. Sionna financial statements analysis is a perfect complement when working with Sionna Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Sionna Stock
Check out the analysis of Sionna Therapeutics Correlation against competitors.

Sionna Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets119.2 M213.6 M100.4 M
Slightly volatile
Other Current Liabilities8.2 M9.4 M7.8 M
Slightly volatile
Total Current Liabilities9.8 M12 M8.7 M
Slightly volatile
Property Plant And Equipment NetM11.8 M4.5 M
Slightly volatile
Accounts Payable902.7 K1.4 M671.3 K
Slightly volatile
Cash35 M34 M50.5 M
Slightly volatile
Non Current Assets Total42 M40 M10.3 M
Slightly volatile
Non Currrent Assets Other4.8 M4.5 M1.6 M
Slightly volatile
Cash And Short Term Investments98.5 M169.7 M89.9 M
Slightly volatile
Common Stock Shares Outstanding35.3 M39.7 M43.3 M
Slightly volatile
Liabilities And Stockholders Equity119.2 M213.6 M100.4 M
Slightly volatile
Non Current Liabilities Total237.2 M389.9 M180.1 M
Slightly volatile
Other Current Assets4.2 MM1.7 M
Slightly volatile
Total Liabilities247 M401.9 M188.8 M
Slightly volatile
Property Plant And Equipment Gross10.1 M13.6 M5.1 M
Slightly volatile
Total Current Assets100.5 M173.6 M91.4 M
Slightly volatile
Capital Stock3.3 K5.8 K2.5 K
Slightly volatile
Net Working Capital90.7 M161.7 M82.7 M
Slightly volatile
Common Stock3.3 K5.8 K2.5 K
Slightly volatile
Short and Long Term Debt Total8.1 M8.8 M10.2 M
Slightly volatile
Short Term Debt990 K1.2 M793.3 K
Slightly volatile

Sionna Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Interest Income9.9 M9.4 M2.6 M
Slightly volatile
Interest Income9.9 M9.4 M2.6 M
Slightly volatile
Depreciation And Amortization503.4 K768.2 K241.7 K
Slightly volatile
Selling General Administrative10.9 M15.3 M8.1 M
Slightly volatile
Other Operating Expenses59.5 M81.1 M47 M
Slightly volatile
Research Development48.6 M65.9 M39 M
Slightly volatile
Total Operating Expenses59.3 M80.4 M46.9 M
Slightly volatile
Reconciled Depreciation503.4 K768.2 K241.7 K
Slightly volatile
Total Other Income Expense Net10.7 M10.2 M2.8 M
Slightly volatile
Cost Of Revenue534.4 K601.2 K656.2 K
Slightly volatile

Sionna Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation2.8 M4.3 M2.1 M
Slightly volatile
Begin Period Cash Flow38.7 M45.4 M18.4 M
Slightly volatile
Other Cashflows From Financing Activities106.3 M205.8 M113.7 M
Pretty Stable
Depreciation503.4 K768.2 K241.7 K
Slightly volatile
Capital Expenditures23.1 K24.3 K1.5 M
Slightly volatile
Total Cash From Financing Activities106.3 M205.8 M113.7 M
Pretty Stable
End Period Cash Flow35.7 M34.9 M51.4 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Capex To Depreciation0.04420.046511.8667
Slightly volatile
Payables Turnover0.450.510.5534
Slightly volatile
Cash Per Share1.623.011.9521
Pretty Stable
Days Payables Outstanding518583637
Slightly volatile
Income Quality0.980.85570.9054
Slightly volatile
ROE0.50.430.5411
Slightly volatile
Net Debt To EBITDA0.840.461.1498
Slightly volatile
Current Ratio7.8713.0410.1371
Very volatile
Capex Per Share7.0E-47.0E-40.0341
Slightly volatile
Interest Debt Per Share0.250.22090.2379
Pretty Stable
Debt To Assets0.05730.06040.1761
Slightly volatile
Days Of Payables Outstanding518583637
Slightly volatile
Ebt Per Ebit1.021.010.9699
Very volatile
Quick Ratio7.8713.0410.1371
Very volatile
Cash Ratio5.524.176.1463
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.131.151.0577
Slightly volatile
Debt Ratio0.05730.06040.1761
Slightly volatile
Return On Equity0.50.430.5411
Slightly volatile

Sionna Fundamental Market Drivers

About Sionna Therapeutics Financial Statements

Sionna Therapeutics investors utilize fundamental indicators, such as revenue or net income, to predict how Sionna Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Cost Of Revenue601.2 K534.4 K

Pair Trading with Sionna Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sionna Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sionna Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Sionna Stock

  0.67DMAC DiaMedica TherapeuticsPairCorr

Moving against Sionna Stock

  0.71RAC Race OncologyPairCorr
  0.61AVH Avita MedicalPairCorr
  0.56VALN Valneva SE ADRPairCorr
  0.53DRMA Dermata TherapeuticsPairCorr
  0.34VANI Vivani MedicalPairCorr
The ability to find closely correlated positions to Sionna Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sionna Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sionna Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sionna Therapeutics Common to buy it.
The correlation of Sionna Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sionna Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sionna Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sionna Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Sionna Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sionna Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sionna Therapeutics Common Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sionna Therapeutics Common Stock:
Check out the analysis of Sionna Therapeutics Correlation against competitors.
You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sionna Therapeutics. If investors know Sionna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sionna Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.80)
Return On Assets
(0.19)
Return On Equity
(0.28)
The market value of Sionna Therapeutics is measured differently than its book value, which is the value of Sionna that is recorded on the company's balance sheet. Investors also form their own opinion of Sionna Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sionna Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sionna Therapeutics' market value can be influenced by many factors that don't directly affect Sionna Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sionna Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sionna Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sionna Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.